-
Signature
-
/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening
-
Issuer symbol
-
CALX
-
Transactions as of
-
02 Jun 2025
-
Net transactions value
-
-$4,029,310
-
Form type
-
4
-
Filing time
-
03 Jun 2025, 16:25:16 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Weening Michael |
President & CEO, Director |
C/O CALIX, INC., 2777 ORCHARD PARKWAY, SAN JOSE |
/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening |
03 Jun 2025 |
0001678385 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
(CALX) |
Common Stock |
Options Exercise |
$510,400 |
+80,000 |
+506% |
$6.38 |
95,812 |
02 Jun 2025 |
Direct |
|
| transaction |
(CALX) |
Common Stock |
Options Exercise |
$119,000 |
+20,000 |
+21% |
$5.95 |
115,812 |
02 Jun 2025 |
Direct |
|
| transaction |
(CALX) |
Common Stock |
Sale |
$4,658,710 |
-100,000 |
-86% |
$46.59 |
15,812 |
02 Jun 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
(CALX) |
Stock Option (right to buy) |
Options Exercise |
$0 |
-80,000 |
-100% |
$0.000000 |
0 |
02 Jun 2025 |
Common Stock |
80,000 |
$6.38 |
Direct |
F2 |
| transaction |
(CALX) |
Stock Option (right to buy) |
Options Exercise |
$0 |
-20,000 |
-9.8% |
$0.000000 |
184,000 |
02 Jun 2025 |
Common Stock |
20,000 |
$5.95 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
Remarks:
Sales reported on the Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan.